Imricor Adds Oklahoma Heart Institute as Fourth U.S. Site in VISABL-AFL Trial

Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh ( (AU:IMR) ) has issued an announcement.

Imricor Medical Systems has added Oklahoma Heart Institute as the fourth U.S. hospital site in its VISABL-AFL clinical trial, which is designed to support U.S. FDA approval of the company’s MRI-guided cardiac ablation products. Oklahoma Heart Institute’s cardiology-owned MRI infrastructure is expected to simplify implementation of interventional cardiac MRI procedures and, alongside existing U.S. and European trial centres, accelerate patient recruitment, shorten the approval timeline, and enable European sites to return sooner to revenue-generating clinical activity, potentially strengthening Imricor’s position in the evolving market for MRI-guided electrophysiology.

The most recent analyst rating on (AU:IMR) stock is a Hold with a A$2.00 price target. To see the full list of analyst forecasts on Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:IMR Stock Forecast page.

More about Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh

Imricor Medical Systems, Inc. is a medical technology company focused on interventional cardiac MRI (iCMR), developing MRI-compatible electrophysiology mapping systems and ablation catheters aimed at improving cardiac ablation procedures. Its products, including the NorthStar 3D Mapping System and Vision-MR catheters, target hospitals with advanced cardiac MRI infrastructure, particularly cardiology-led facilities that can integrate MRI-guided electrophysiology with lower capital and organisational barriers to adoption.

Average Trading Volume: 243,202

Technical Sentiment Signal: Buy

Current Market Cap: A$634.5M

For a thorough assessment of IMR stock, go to TipRanks’ Stock Analysis page.